Findings and insights from the genetic investigation of age of first reported occurrence for complex disorders in the UK Biobank and FinnGen

Competing Interest Statement

J.W.S is an unpaid member of the Bipolar/Depression Research Community Advisory Panel of 23andMe, a member of the Leon Levy Foundation Neuroscience Advisory Board and received an honorarium for an internal seminar at Biogen, Inc. He is PI of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments. B.M.N. is a member of the Deep Genomics Scientific Advisory Board and serves as a consultant for the Camp4 Therapeutics Corporation, Takeda Pharmaceutical and Biogen. The remaining authors declare no conflict of interests.

Funding Statement

We would like to acknowledge the participants and investigators of the UK Biobank and the FinnGen study for their gracious contribution. This research has been conducted using the UK Biobank Resource under Application Numbers 31063 and 32568. T.G. is supported by the National Institutes of Health (NIH) grant K99/R00 AG054573.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The UK Biobank and FinnGen datasets analyzed in the present work were requested through applications and were approved for research use in our study. The UK Biobank Resource is open to the public and was obtained under Application Numbers 31063 and 32568 by our group. For each participant in the UK Biobank, an electronically signed consent was obtained at recruitment, who then provided as part of the data collection their demographic information, health-related conditions as well as biological samples (e.g., blood, saliva) for genetic and other -omics data generation. All the individual-level information in the dataset is de-identified. Our access to the FinnGen study is obtained through a research proposal with Dr. Andrea Ganna, a consortium partner of FinnGen and a co-author of the work, which granted only sharing of results but not individual-level data sharing. All the genetic analyses of the FinnGen cohort presented in the manuscript were performed by Dr. Ganna's group, and the summary tables (e.g, heritability, genetic correlation estimates) were then shared with the first author for plotting and writing purposes. The FinnGen study is a registry-based cohort that includes all Finnish biobanks and hospital-based cohorts in Finland, in which all participants were asked to provide informed consent, either electronically or written, to donate his or her samples before joining the biobank. Both UK Biobank and FinnGen cohorts updates informed consent regularly. Our study has carefully removed any individuals who have since withdrawn consent prior to data analysis.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes